The FDA has confirmed that SeaStar Medical has fulfilled the post-approval study requirements for its QUELIMMUNE therapy, used to treat sepsis-associated acute kidney injury (AKI) in critically ill pediatric patients. This decision allows broader hospital access to the therapy without the previous research restrictions, potentially improving survival rates for children with life-threatening AKI. Data from the SAVE Registry showed a significant survival benefit with QUELIMMUNE compared to standard care. SeaStar Medical plans to continue collecting real-world data while expanding the therapy's availability.
SeaStar Medical's FDA confirmation on QUELIMMUNE offers context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Nov 03, 2026 20:11 WIB: Out of 150 health-sector US stocks, 75 rose and 69 fell. Notable gainers include PHG at USD 29.00 (+5.11%), NUVB at USD 4.81 (+4.79%), and ACB at USD 4.38 (+3.79%).
Vencora has acquired CT InsureTech, a leading insurance technology provider with offices in London, Buenos Aires, and Mexico City. This acquisition strengthens Vencora's insurance technology offerings and expands its presence in Latin America and Eur...
Vencora has acquired CT InsureTech, a leading provider of insurance technology and services with offices in London, Buenos Aires, and Mexico City. This acquisition expands Vencora's portfolio and presence in Latin America and the UK, strengthening it...
The Hospitality Show, a key event for hotel operations, will return to Las Vegas from March 27–29, 2028, at the Las Vegas Convention Center. This marks a return to its original location and an earlier spring date, chosen to better align with hospital...
FarmQA and Planet Labs have partnered to develop AI-powered agronomic tools for enterprise agriculture, starting with a sugar beet yield estimation model. This model combines Planet's satellite imagery with FarmQA's field-verified agronomic data to p...
The global Automatic FOUP Opener Market is projected to grow from USD 4.41 billion in 2026 to USD 6.04 billion by 2032, expanding at a CAGR of 5.36%. Growth is driven by increasing fab automation, stricter contamination control requirements, and dema...
